出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2016/03/27 06:30:07」(JST)
| Thrombocytopenia | |
|---|---|
|
A picture of the blood under a microscopy showing thrombocytopenia
|
|
| Classification and external resources | |
| ICD-10 | D69.6 |
| ICD-9-CM | 287.5 |
| Patient UK | Thrombocytopenia |
|
[edit on Wikidata]
|
|
Thrombocytopenia and thrombopenia refer to a disorder in which there is a relative decrease of thrombocytes, commonly known as platelets, present in the blood.[1]
A normal human platelet count ranges from 150,000 to 450,000 platelets per microliter of blood.[2] These limits are determined by the 2.5th lower and upper percentile, so values outside this range do not necessarily indicate disease. One common definition of thrombocytopenia that requires emergency treatment is a platelet count below 50,000 per microliter.[3]
Thrombocytopenia usually has no symptoms and is picked up on a routine full blood count (or complete blood count). Some individuals with thrombocytopenia may experience external bleeding such as nosebleeds, and/or bleeding gums. Some women may have heavier or longer periods or breakthrough bleeding. Bruising, particularly purpura in the forearms, may be caused by spontaneous bleeding under the skin. Petechia (pinpoint bleeds in the skin and mucous membranes), may occur on feet and legs.[4][5]
Eliciting a full medical history is vital to ensure the low platelet count is not due to a secondary process. It is also important to ensure that the other blood cell types, such as red blood cells and white blood cells, are not also suppressed.[4] Painless, round and pinpoint (1 to 3 mm in diameter) petechiae usually appear and fade, and sometimes group to form ecchymoses. Larger than petechiae, ecchymoses are purple, blue or yellow-green areas of skin that vary in size and shape. They can occur anywhere on the body.[4]
A person with this disease may also complain of malaise, fatigue and general weakness (with or without accompanying blood loss). In acquired thrombocytopenia, the patient's history may include the use of one or several offending drugs. Inspection typically reveals evidence of bleeding (petechiae or ecchymoses), along with slow, continuous bleeding from any injuries or wounds. Adults may have large, blood-filled bullae in the mouth.[6] If the person's platelet count is between 30,000 and 50,000/mm3, bruising with minor trauma may be expected; if it is between 15,000 and 30,000/mm3, spontaneous bruising will be seen (mostly on the arms and legs).[7]
The causes of thrombocytopenia can be inherited or acquired.[8]
Can be due to the following reasons:[9]
can be due to immune or non-immune reasons.[10]
Thrombocytopenia-inducing medications include:[11]
Laboratory tests might include: full blood count, liver enzymes, kidney function, vitamin B12 levels, folic acid levels, erythrocyte sedimentation rate, and peripheral blood smear. If the cause for the low platelet count remains unclear, a bone marrow biopsy is usually recommended, to differentiate whether the low platelet count is due to decreased production or peripheral destruction.[15]
Thrombocytopenia in hospitalized alcoholics may be caused by spleen enlargement, folate deficiency, and, most frequently, a direct toxic effect of alcohol on production, survival time, and function of platelets.[16] Platelet count begins to rise after 2 to 5 days' abstinence from alcohol. The condition is generally benign, and clinically significant hemorrhage is rare. In severe thrombocytopenia, a bone marrow study can determine the number, size and maturity of the megakaryocytes (the bone marrow cells that release mature platelets). This information may identify ineffective platelet production as the cause of thrombocytopenia and rule out a malignant disease process at the same time.[17]
Treatment is guided by the cause and disease severity. The main concept in treating thrombocytopenia is to eliminate the underlying problem, whether that means discontinuing suspected drugs that cause thrombocytopenia, or treating underlying sepsis. Diagnosis and treatment of serious thrombocytopenia is usually directed by a hematologist.Corticosteroids may be used to increase platelet production. Lithium carbonate or folate may also be used to stimulate the bone marrow production of platelets.[18]
Treatment of thrombotic thrombocytopenic purpura is a medical emergency, since the hemolytic anemia and platelet activation can lead to renal failure and changes in the level of consciousness. Treatment of TTP was revolutionized in the 1980s with the application of plasmapheresis. According to the Furlan-Tsai hypothesis [19] this treatment theoretically works by removing antibodies directed against the von Willebrand factor cleaving protease, ADAMTS-13. The plasmapheresis procedure also adds active ADAMTS-13 protease proteins to the patient, restoring a more physiological state of von Willebrand factor multimers. Patients with persistent antibodies against ADAMTS-13 do not always manifest TTP, and these antibodies alone are not sufficient to explain how plasmapheresis treats TTP.[20]
Many cases of ITP can be left untreated, and spontaneous remission (especially in children) is not uncommon. However, counts of under 50,000 are usually monitored with regular blood tests, and those with counts of under 10,000 are usually treated, as the risk of serious spontaneous bleeding is high with a platelet count this low. Any patient experiencing severe bleeding symptoms is also usually treated. The threshold for treating ITP has decreased since the 1990s, and hematologists recognize that patients rarely spontaneously bleed with platelet counts greater than 10,000—though there are documented exceptions to this observation.[21][22]
Thrombopoetin analogues have been tested extensively for the treatment of ITP. These agents had previously shown promise but had been found to stimulate antibodies against endogenous thrombopoietin or lead to thrombosis.Romiplostim (trade name Nplate, formerly AMG 531) was found to be safe and effective for the treatment of ITP in refractory patients, especially those who relapsed following splenectomy.[23]
Discontinuation of heparin is critical in a case of HITT. Beyond that, however, clinicians generally treat to avoid a thrombosis, and patients started directly on warfarin [24] For this reason, patients are usually treated with a type of blood thinner called a direct thrombin inhibitor such as lepirudin or argatroban, which are approved by the U.S. Food and Drug Administration (FDA). Other blood thinners sometimes used in this setting that are not FDA-approved for treatment of HITT include bivalirudin and fondaparinux. Platelet transfusions are not a routine component of the treatment of HITT, since thrombosis, not bleeding, is the usual associated problem in this illness.[25]
Bone marrow/stem cell transplant is the only thing that ultimately cures this genetic disease. Frequent platelet transfusions are required to keep the patient from bleeding to death until transplant is done, although this is not always the case.[26]
Thrombocytopenia affects a few percent of newborns, and its prevalence in neonatal intensive care units (NICU) is high. Normally, its course is mild and it resolves without consequences. Most of the cases of thrombocytopenia affect preterm birth infants and are results of placental insufficiency and/or fetal hypoxia. The other causes are less frequent, e.g. alloimmune, genetic, autoimmune, infection, and DIC.[27]
Thrombocytopenia that starts after the first 72 hours since birth is often the result of underlying sepsis or necrotizing enterocolitis (NEC).[27] In the case of infection the PCR tests may be useful for rapid pathogen identification and detection of antibiotic resistance genes. The possible pathogens may be fungus, bacteria and viruses, for example: Cytomegalovirus (CMV),[27] rubella virus,[27] HIV,[27] Staphylococcus sp.,[28] Enterococcus sp.,[28] Streptococcus agalactiae (GBS),[27] Listeria monocytogenes,[29] Escherichia coli,[27][28] Haemophilus influenzae,[27] Klebsiella pneumoniae,[28] Pseudomonas aeruginosa,[28][30] Yersinia enterocolitica,[30] Candida sp.,[28] and Toxoplasma gondii.[27] The severity of thrombocytopenia might be correlated with the type of a pathogen; some research indicates that the most severe cases are related to fungal or gram-negative bacterial infection.[28] The pathogen may be transmitted during birth[31] or prior to it, but also by breast feeding[32][33][34] or during transfusion.[35] Interleukin-11 is being investigated as a potential drug for aiding thrombocytopenia management, especially in the cases of sepsis or necrotizing enterocolitis (NEC).[27]
|
||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
| リンク元 | 「サイトカイン」「血小板減少症」「出血性疾患」 |
| 拡張検索 | 「neonatal alloimmune thrombocytopenia」「heparin-induced thrombocytopenia」「drug-induced immune thrombocytopenia」「immune thrombocytopenia」「immunothrombocytopenia」 |
| 機能 | サブグループ | サイトカイン | 標的 | 機能 |
| 炎症性サイトカイン | TNFファミリー | TNF-α | 白血球、上皮細胞 | 活性化 |
| インターロイキン | IL-1 | 上皮細胞、リンパ球 | 活性化 | |
| IL-6 | 種々の細胞 | 活性化 | ||
| IL-8 | 白血球 | 炎症部位遊走 | ||
| T細胞の増殖・分化 | インターロイキン | IL-2 | T細胞 | 活性化。増殖 |
| IL-4 | T細胞 | 増殖 | ||
| Th2細胞 | 分化誘導 | |||
| IL-12 | Th1細胞 | 分化誘導 | ||
| インターフェロン | IFN-γ | Th2細胞 | 分化抑制 | |
| B細胞の増殖・分化 | インターロイキン | IL-2 | B細胞 | 活性化 |
| IL-4 | B細胞 | 活性化、増殖、分化 | ||
| IL-5 | B細胞 | 活性化、増殖 | ||
| IL-6 | B細胞 | 増殖、分化 | ||
| TGF-β | B細胞 | 分化(IgA分泌) | ||
| アレルギー調節サイトカイン | インターロイキン | IL-3 | 肥満細胞 | 増殖、分化促進 |
| IL-4 | B細胞 | IgEクラススイッチ促進 | ||
| IL-5 | 好酸球 | 増殖、分化促進 | ||
| IL-13 | B細胞 | IgEクラススイッチ促進 | ||
| インターフェロン | IFN-γ | B細胞 | IgEクラススイッチ抑制 | |
| 走化性サイトカイン(ケモカイン) | CCケモカイン | MIP-1 | 好中球 | 遊走 |
| MIP-2 | ||||
| RANTES | 単球 | |||
| CXCケモカイン | IL-8 | 好中球、リンパ球、好塩基球 | ||
| SDF-1 | ||||
| 造血系サイトカイン | SCF | |||
| インターロイキン | IL-7 | |||
| erythropoietin | ||||
| コロニー刺激因子 | GM-CSF | |||
| G-CSF | ||||
| M-CSF |
| agent | clinical uses | |
| aldesleukin | interleukin-2 | renal cell carcinoma, metastatic melanoma |
| erythropoietin | epoetin | anemias (especially in renal failure) |
| filgrastim | granulocyte colony-stimulating factor | recovery of bone marrow |
| sargramostim | granulocyte-macrophage colony stimulating factor | recovery of bone marrow |
| α-interferon | hepatitis B and C, Kaposi's sarcoma, leukemias, malignant melanoma | |
| β-interferon | multiple sclerosis | |
| γ-interferon | chronic granulomatous disease | |
| oprelvekin | interleukin-11 | thrombocytopenia |
| thrombopoietin | thrombocytopenia | |
| Disorder | platelet count | bleeding time | PT . | PTT . |
| qualitative platelet defects | － | ↑ | － | － |
| thrombocytopenia | ↓ | ↑ | － | － |
| hemophilia A or hemophilia B | － | － | － | ↑ |
| von Willebrand's disease | － | ↑ | － | ↑ |
| DIC | ↓ | ↑ | ↑ | ↑ |